Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 76 entries
View as:

A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00873561 Org: User:
Start: 12/31/01 End: 07/31/06 Due: 07/31/07

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02679079 Org: User:
Start: 03/23/16 End: 04/14/17 Due: 04/14/18

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Phase: N/A Priority: Normal
NCT ID: NCT03698331 Org: User:
Start: 09/14/18 End: 04/03/19 Due: 04/03/20

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase: N/A Priority: Normal
NCT ID: NCT05301894 Org: User:
Start: 06/07/22 End: 01/27/25 Due: 01/27/26

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Phase: N/A Priority: Normal
NCT ID: NCT03062033 Org: User:
Start: 04/04/17 End: 08/31/18 Due: 08/31/19

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Phase: N/A Priority: Normal
NCT ID: NCT04400331 Org: User:
Start: 09/18/20 End: 03/31/26 Due: 03/31/27

Opicapone Treatment Initiation Open-Label Study

Phase: N/A Priority: Normal
NCT ID: NCT04787965 Org: User:
Start: 03/01/21 End: 08/04/22 Due: 08/04/23

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT06786624 Org: User:
Start: 01/22/25 End: 07/31/27 Due: 07/31/28

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05654870 Org: User:
Start: 01/05/23 End: 11/08/23 Due: 11/08/24

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00014677 Org: User:
Start: 03/31/01 End: 07/31/08 Due: 07/31/09

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02879578 Org: User:
Start: 07/25/16 End: 11/01/17 Due: 11/01/18

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01910480 Org: User:
Start: 07/31/13 End: 08/31/13 Due: 08/31/14

Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

Phase: N/A Priority: Normal
NCT ID: NCT00232167 Org: User:
Start: 11/30/05 End: 04/30/06 Due: 04/30/07

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Phase: N/A Priority: Normal
NCT ID: NCT03792672 Org: User:
Start: 02/11/19 End: 06/18/19 Due: 06/18/20

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05182476 Org: User:
Start: 12/07/21 End: 10/14/24 Due: 10/14/25

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT06963021 Org: User:
Start: 05/31/25 End: 07/31/27 Due: 07/31/28

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03444038 Org: User:
Start: 02/08/18 End: 07/12/19 Due: 07/12/20

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Phase: N/A Priority: Normal
NCT ID: NCT01393600 Org: User:
Start: 08/31/11 End: 02/29/12 Due: 02/28/13

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT01267188 Org: User:
Start: 01/31/11 End: 03/31/11 Due: 03/31/12

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Phase: N/A Priority: Normal
NCT ID: NCT03101293 Org: User:
Start: 04/04/17 End: 05/26/17 Due: 05/26/18

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

Phase: N/A Priority: Normal
NCT ID: NCT03733496 Org: User:
Start: 08/24/18 End: 07/18/23 Due: 07/18/24

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT02736955 Org: User:
Start: 06/13/16 End: 06/30/17 Due: 06/30/18

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT06966401 Org: User:
Start: 05/31/25 End: 05/31/30 Due: 05/31/31

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Phase: N/A Priority: Normal
NCT ID: NCT04102579 Org: User:
Start: 11/13/19 End: 10/26/21 Due: 10/26/22

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02581865 Org: User:
Start: 11/30/15 End: 12/31/16 Due: 12/31/17